Amneal Pharmaceuticals (NASDAQ:AMRX) vs. Neurocrine Biosciences (NASDAQ:NBIX) Head-To-Head Survey

Amneal Pharmaceuticals (NASDAQ:AMRX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Amneal Pharmaceuticals and Neurocrine Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0	2	8	0	2.80
Neurocrine Biosciences	0	4	19	1	2.88

Amneal Pharmaceuticals currently has a consensus target price of $23.00, indicating a potential upside of 5.94%. Neurocrine Biosciences has a consensus target price of $202.32, indicating a potential upside of 16.00%. Given Neurocrine Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.

Institutional & Insider Ownership

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amneal Pharmaceuticals and Neurocrine Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.17%	283.50%	7.79%
Neurocrine Biosciences	18.98%	23.39%	16.22%

Valuation & Earnings

This table compares Amneal Pharmaceuticals and Neurocrine Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02 billion	2.30	$72.06 million	$0.42	51.69
Neurocrine Biosciences	$2.86 billion	6.17	$478.60 million	$6.74	25.88

Neurocrine Biosciences has lower revenue, but higher earnings than Amneal Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Neurocrine Biosciences beats Amneal Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.

About Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.